The inclusion of fractional flow reserve (FFR) has changed how coronary interventions are treated. Current guidelines endorse its use in intermediate lesions with no evidence of ischemia in non-invasive studies in patients with multivessel disease. The original RIPCORD (Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain) study proposed<a href="https://solaci.org/en/2022/09/12/ripcord-2-study-routine-assessment-using-pressure-wires-in-acute-coronary-syndrome/" title="Read more" >...</a>
Is TCA Useful for Severe Impairment of Left Ventricular Ejection Fraction?
Heart disease is the most frequent cause of heart failure and, in some observational studies, transluminal coronary angioplasty (TCA) could help improve ventricular function. The only major randomized study to compare myocardial revascularization surgery (MRS) vs. medical treatment in patients with ventricular function impairment was the STICH study, which showed no difference at 5 years,<a href="https://solaci.org/en/2022/09/06/is-tca-useful-for-severe-impairment-of-left-ventricular-ejection-fraction/" title="Read more" >...</a>
Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL
About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do<a href="https://solaci.org/en/2022/07/21/tricuspid-regurgitation-edge-to-edge-treatment-with-pascal/" title="Read more" >...</a>
Coronary Bifurcation Lesions: MRS or PCI? 10-Year Mortality of the SYNTAX Study
Percutaneous treatment of coronary lesions affecting bifurcations has increased in recent decades. Coronary angioplasty (percutaneous coronary intervention, PCI) in these cases is associated with an increased rate of adverse events in patients with multivessel disease and left main coronary artery lesions. The SYNTAX score, which is a predictor of total mortality, is used to evaluate<a href="https://solaci.org/en/2022/07/01/coronary-bifurcation-lesions-mrs-or-pci-10-year-mortality-of-the-syntax-study/" title="Read more" >...</a>
In Multivessel Disease, When Should Renal Impairment Be Considered?
Cardiovascular disease is one of the main causes of morbidity and mortality in patients with advanced chronic kidney disease (CKD), and vice-versa. Both diseases share risk factors, including, but not limited to, diabetes, high blood pressure, smoking, dyslipidemia, and old age. As kidney disease develops, its severity grade has been linked to more thrombotic events<a href="https://solaci.org/en/2022/04/27/in-multivessel-disease-when-should-renal-impairment-be-considered/" title="Read more" >...</a>
MitraClip Failure: What Should We Do?
Currently, edge-to-edge therapy with MitraClip has demonstrated efficacy and safety for the treatment of patients with degenerative or functional mitral regurgitation who are at high risk for surgery. However, device-related complications are still present—though their frequency is subsiding due to greater experience, 3D doppler echocardiography development, and technological advancements: loss of leaflet insertion (LLI), single<a href="https://solaci.org/en/2022/03/10/mitraclip-failure-what-should-we-do/" title="Read more" >...</a>
Bypass Grafting and Native Coronary Artery Disease Activity
Positron emission tomography (PET) with F sodium fluoride (F-NaF) allows for the assessment of microcalcification activity (MA) in a wide variety of cardiovascular conditions, including atherosclerosis. In coronary artery disease, this tracer correlates with progressive disease and allows for the prediction of atherosclerosis progression. Unlike PETs, computed tomography (CT) allows for the evaluation of an<a href="https://solaci.org/en/2022/03/04/bypass-grafting-and-native-coronary-artery-disease-activity/" title="Read more" >...</a>
Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight
Yet another observational study has come to question the antiaggregation power of ticagrelor when it comes to death or MI reduction, pointing at its higher risk of bleeding vs. clopidogrel. This new analysis recently published in JAHA includes a large number of patients undergoing acute coronary syndrome (ACS) in the clinical practice. Ticagrelor has been<a href="https://solaci.org/en/2021/04/28/back-to-basics-ticagrelor-questioned-and-clopidogrel-in-the-limelight/" title="Read more" >...</a>
The Most Read Articles in Interventional Cardiology during February
01- Efficacy of AstraZeneca’s Vaccine against COVID-19 This study, published in the Lancet, looks into the vaccine resulting from the collaboration of the Oxford University and AstraZeneca, among others. Read more HERE 02- Findings on Sputnik V Vaccine Against COVID-19 The Sputnik V vaccine was developed by Gamaleya NRCEM. Similarly to the Oxford-AstraZeneca vaccine, it is based on a viral vector,<a href="https://solaci.org/en/2021/03/03/the-most-read-articles-in-interventional-cardiology-during-february/" title="Read more" >...</a>
FREEDOM with FFR: Different Outcomes?
The FREEDOM has clearly established the benefit of myocardial revascularization surgery (CABG) over percutaneous coronary intervention (PCI) in diabetic patients with multivessel disease. Coronary physiology as guideline for revascularization works best precisely in this kind of patients and its impact has never been studied in diabetics. This study, published in Circ Cardiovasc Interv, assessed the<a href="https://solaci.org/en/2021/02/17/freedom-with-ffr-different-outcomes/" title="Read more" >...</a>